Literature DB >> 20099058

Insufficient evaluation of adverse events is not a proof of safety.

L G Hemkens, U Grouven, R Bender, P T Sawicki.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20099058     DOI： 10.1007/s00125-009-1654-7

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  7 in total

1.  Adverse events in randomized trials: neglected, restricted, distorted, and silenced.

Authors:  John P A Ioannidis
Journal:  Arch Intern Med       Date:  2009-10-26

2.  Combined randomised controlled trial experience of malignancies in studies using insulin glargine.

Authors:  P D Home; P Lagarenne
Journal:  Diabetologia       Date:  2009-09-15       Impact factor: 10.122

3.  Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.

Authors:  L G Hemkens; U Grouven; R Bender; C Günster; S Gutschmidt; G W Selke; P T Sawicki
Journal:  Diabetologia       Date:  2009-06-30       Impact factor: 10.122

4.  The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.

Authors:  C J Currie; C D Poole; E A M Gale
Journal:  Diabetologia       Date:  2009-07-02       Impact factor: 10.122

5.  Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden.

Authors:  J M Jonasson; R Ljung; M Talbäck; B Haglund; S Gudbjörnsdòttir; G Steineck
Journal:  Diabetologia       Date:  2009-07-09       Impact factor: 10.122

6.  Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.

Authors:  H M Colhoun
Journal:  Diabetologia       Date:  2009-07-15       Impact factor: 10.122

7.  Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study.

Authors:  J Rosenstock; V Fonseca; J B McGill; M Riddle; J P Hallé; I Hramiak; P Johnston; M Davis
Journal:  Diabetologia       Date:  2009-07-16       Impact factor: 10.122
  7 in total
  1 in total

1.  Long-term effects of insulin glargine on the risk of breast cancer.

Authors:  S Suissa; L Azoulay; S Dell'Aniello; M Evans; J Vora; M Pollak
Journal:  Diabetologia       Date:  2011-05-26       Impact factor: 10.122
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.